Lyon Gerland: laying of the first stone of Gerland 2, Aguettant's future production site, on 4 July 2013
25 July 2013
The independent French pharmaceutical laboratory Aguettant is building a new site at its historic location, in the heart of the Biopôle in Lyon Gerland. The first stone of "Gerland 2" was laid on 4 July 2013, at Rue Alexandre Fleming.
Gerland 2, innovation in the service of research
A pioneer in injectable solutions, Aguettant specialises in particular in emergency medicines, nutrition and Parkinson's disease. On its site in Lyon Gerland, the Lyon-based laboratory focuses on the production of technically advanced medicines with a high medical value.
With a turnover of EUR 87 million announced in 2012, Aguettant is continuing its development and is investing EUR 22 million in the Gerland 2 project. The objective? To modernise its production to meet quality standards compatible with the requirements of international pharmaceutical markets.
Gerland 2, conquering international markets
"Today, around 20% of our activity is achieved internationally," states the chairman of the supervisory board Eric Rougemond. For the horizon of 2016, the independent pharmaceutical laboratory has every intention of being one of the global businesses in the sector. "In this regard, Gerland 2 is the first external sign of our corporate project."
In this context, the future site will have a modern production tool and better R&D capacities which will foster innovation. It will comply with the most stringent pharmaceutical guidelines and will place the emphasis on safety and the environment.
The construction, fitting and qualification works for Gerland 2 which commenced in Summer 2012 should last 2 years, while the site is expected to become operationally active in mid-2015.